We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares

Delisted

FUSN was delisted on the 3rd of June, 2024.

31 hedge funds and large institutions have $61.3M invested in Fusion Pharmaceuticals Inc. Common Shares in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

11% more funds holding

Funds holding: 2831 (+3)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

72% less capital invested

Capital invested by funds: $219M → $61.3M (-$158M)

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.52%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
4
Increased
2
Reduced
8
Closed
1
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
-$5K

FUSN Hedge Fund Activity: Q2 2022 in Review

31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2022, worth a combined $61.3M — down 72% from $219M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new FUSN positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 8 trimmed.

The largest buyer was Federated Hermes, adding an estimated $317K. The largest seller was Perceptive Advisors, cutting an estimated $802K.

  • 31 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2022, up from 28 in Q1 2022.
  • Funds reported $61.3M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2022, down 72% quarter-over-quarter.
  • 4 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2022 and 1 closed out, a net change of +3 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2022 was Federated Hermes, an estimated $317K added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2022 was Perceptive Advisors, an estimated $802K sold.

Based on aggregated 13F filings for Q2 2022.